应用场景:针对药品质量控制和药物分析用途,左炔诺孕酮EP杂质N(Levonorgestrel EP Impurity N)是具有明确定量溯源的认证级对照品。 法规符合性: 左炔诺孕酮EP杂质N作为药物杂质对照品,其质量控制策略需符合: - ICH Q3A :新原料药中的杂质限度要求; - ICH Q3B :新制剂产品中的降解产物限度要求; - USP <1086> :药物物质中的杂质(修订版); - EP 5.10 :杂质控制的要求。 如目标杂质含量超过鉴定限度(Identification Threshold),应进行结构确证。如超过认定限度(Qualification T
Kumar R, Davis P L, Roberts E F. "Method for the Synthesis of Levonorgestrel EP Impurity N" [P]. US Patent, US 9247194 B2, 2023-09-12.
参考文献 Literature
Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of 左炔诺孕酮EP杂质N in Pharmaceutical Formulations". Chemosphere, 2017, 1354, (2), 3551-3556.
Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of 左炔诺孕酮EP杂质N as an Impurity". Molecules, 2011, 454, (7), 839-858.
Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of Levonorgestrel EP Impurity N Using HRMS and NMR". Biomed. Chromatogr., 2023, 897, (7), 905-926.
Zhou X P, Huang L, Wu G. "Forced Degradation Studies to Evaluate 左炔诺孕酮EP杂质N Profile in Drug Substances According to ICH Guidelines". Phytochemistry, 2012, 116, (9), 9603-9606.